PMPRB Revised Draft Guidelines: Ambiguity could further reduce availability of new medicines for Canadians

Innovative Medicines Canada’s (IMC) initial interpretation of the Patented Medicine Prices Review Board’s (PMPRB) revised draft Guidelines is that they will further reduce the availability of new medicines in Canada by exacerbating an already unpredictable regulatory environment.

NewsGuest UserNovember 7, 2022BIOOQuébecbiotechnology, drone technology, pmprb, Innovative Medicine Canada

RENEWAL OF INNOVATIVE MEDICINE CANADA AGREEMENT

The agreement reached between IMC (then Rx&D) and BIOQuébec in 2013, which offers some members of BIOQuébec the opportunity to become a member of IMC for an amount equivalent to 20% of their BIOQuébec membership, will be renewed.

NewsCatherine LamontagneNovember 19, 2018BIOOQuébecAgreement, Innovative Medicine Canada, Membership